Kura Oncology is taking technology originally developed around cancer biology into the enormous diabetes market, launching a new company called Caspian Therapeutics with $50 million in financing to investigate whether menin inhibitors can restore the body\u2019s ability to produce insulin.<\/p>\n\n\n\n
The scientific idea behind Caspian could represent an important departure from many existing diabetes treatments. Instead of primarily controlling blood glucose or replacing insulin, the company hopes to address one of the underlying biological problems in diabetes: the loss or dysfunction of insulin-producing pancreatic beta cells.<\/p>\n\n\n\n
Caspian\u2019s lead experimental drug, KO-7246, is a next-generation oral menin inhibitor specifically designed for chronic metabolic diseases. Menin is a protein involved in cellular signaling and gene regulation. Kura\u2019s research suggests that inhibiting it may remove a biological constraint on beta-cell growth, allowing the pancreas to increase its population of functioning insulin-producing cells.<\/p>\n\n\n\n
The findings remain preclinical, meaning the approach has not yet been proven safe or effective in people with diabetes.<\/p>\n\n\n\n
However, Kura says experiments across models of both Type 1 and Type 2 diabetes showed that menin inhibition selectively increased beta-cell proliferation, expanded functional beta-cell mass, increased the body\u2019s own insulin production and improved glucose control. Researchers also observed effects in human pancreatic-islet laboratory systems.<\/p>\n\n\n\n
Particularly important is the possibility that the benefits could persist after treatment ends. Kura says improvements continued after menin-inhibitor treatment was discontinued in preclinical experiments, raising the possibility that the approach could produce a durable biological change rather than simply lowering glucose while patients take the medicine.<\/p>\n\n\n\n
That is why Caspian describes the strategy as potentially disease-modifying.<\/p>\n\n\n\n
KO-7246 will now have to demonstrate whether those promising laboratory findings translate into humans. The $50 million financing is expected to fund the drug through studies required before clinical testing and into an initial proof-of-concept trial in diabetes. Caspian will also develop a second menin inhibitor for diabetes and other cardiometabolic diseases.<\/p>\n\n\n\n
The financing attracted notable investors.<\/p>\n\n\n\n
BVF Partners led the round, with participation from the T1D Fund, Invus, Montanova, Kura Oncology and members of Kura\u2019s leadership team. Perhaps most significant is the involvement of Eli Lilly, one of the world\u2019s most powerful diabetes and metabolic-disease companies.<\/p>\n\n\n\n
Lilly\u2019s participation provides additional industry validation for an approach that remains scientifically promising but clinically unproven.<\/p>\n\n\n\n
The creation of Caspian also allows Kura to pursue the opportunity without distracting from its primary cancer business.<\/p>\n\n\n\n
Kura has substantial experience developing menin inhibitors in oncology. Drugs targeting menin have already demonstrated that the protein can be successfully targeted therapeutically in certain forms of leukemia. Caspian will attempt to apply that expertise to a completely different biological problem.<\/p>\n\n\n\n
Kura will retain approximately half of Caspian, while the new company receives dedicated leadership and external financing. Kura CEO Troy Wilson will serve as executive chairman of Caspian\u2019s board, and biotechnology executive Robert Spencer will lead the new company.<\/p>\n\n\n\n
The structure allows Kura to remain concentrated on oncology while preserving considerable financial exposure if Caspian succeeds.<\/p>\n\n\n\n
There is also competition. Other biotechnology companies are investigating menin inhibition for diabetes, reflecting growing interest in regenerating beta cells rather than relying exclusively on conventional glucose-management strategies.<\/p>\n\n\n\n
For Caspian, the biggest challenge now is proving that the biological effect observed in laboratory and animal models can be reproduced safely in patients.<\/p>\n\n\n\n
If that happens, the implications could be significant.<\/p>\n\n\n\n
Modern diabetes treatment has been transformed by insulin technologies, continuous glucose monitoring and powerful metabolic drugs such as GLP-1 medicines. Yet these approaches generally do not regenerate the pancreatic beta-cell capacity lost or impaired by diabetes.<\/p>\n\n\n\n
Caspian is pursuing a different possibility: helping the body rebuild some of its own insulin-producing machinery.<\/p>\n\n\n\n
That remains a scientific hypothesis rather than an established treatment. But the combination of $50 million in financing, Kura\u2019s experience with menin biology and backing from major diabetes investors gives Caspian the resources to test it.<\/p>\n\n\n\n
The new company therefore represents an intriguing biotechnology experiment: whether a drug mechanism proven useful in cancer can be redirected toward one of medicine\u2019s largest chronic diseases\u2014and potentially move diabetes treatment beyond managing its consequences toward repairing part of its underlying biology.<\/p>\n","protected":false},"excerpt":{"rendered":"
Kura Oncology is taking technology originally developed around cancer biology into the enormous diabetes market, launching a new company called Caspian Therapeutics with $50 million in financing to investigate whether menin inhibitors can restore the body\u2019s ability to produce insulin. The scientific idea behind Caspian could represent an important departure from many existing diabetes treatments. […]<\/p>\n","protected":false},"author":1,"featured_media":10900,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[221,3904,4079],"tags":[4109,193,2324,1276],"class_list":["post-10906","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-entrepreneurship","category-lifestyle","category-science","tag-diabetes","tag-news","tag-treatments","tag-us"],"_links":{"self":[{"href":"https:\/\/miaminewsnetwork.com\/index.php?rest_route=\/wp\/v2\/posts\/10906","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/miaminewsnetwork.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/miaminewsnetwork.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/miaminewsnetwork.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/miaminewsnetwork.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=10906"}],"version-history":[{"count":1,"href":"https:\/\/miaminewsnetwork.com\/index.php?rest_route=\/wp\/v2\/posts\/10906\/revisions"}],"predecessor-version":[{"id":10907,"href":"https:\/\/miaminewsnetwork.com\/index.php?rest_route=\/wp\/v2\/posts\/10906\/revisions\/10907"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/miaminewsnetwork.com\/index.php?rest_route=\/wp\/v2\/media\/10900"}],"wp:attachment":[{"href":"https:\/\/miaminewsnetwork.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=10906"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/miaminewsnetwork.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=10906"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/miaminewsnetwork.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=10906"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}